Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma

被引：1

作者：

Shi, Diana D. ^{[1
,2
]}

Lee, Joyce H. ^{[3
]}

Wang, Adam C. ^{[3
]}

Khanal, Januka ^{[3
]}

Gao, Wenhua ^{[3
]}

Kaelin Jr, William G. ^{[3
,4
]}

Mcbrayer, Samuel K. ^{[2
,5
,6
]}

机构：

[1] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA

[2] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Ctr Res Inst, Dallas, TX 75390 USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Med Oncol, Boston, MA USA

[4] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA

[5] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dept Pediat, Dallas, TX 75390 USA

[6] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75235 USA

来源：

STAR PROTOCOLS | 2023年 / 4卷 / 02期

关键词：

Cancer; Model Organisms; Neuroscience;

D O I：

10.1016/j.xpro.2023.102281

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Lower-grade gliomas exhibit a high prevalence of isocitrate dehydrogenase 1 (IDH1) mutations, but faithful models for studying these tumors are lacking. Here, we present a protocol to establish a genetically engineered mouse (GEM) model of grade 3 astrocytoma driven by the Idh1R132H oncogene. We describe steps for breeding compound transgenic mice and intracranially delivering adeno-associated virus particles, followed by post-surgical surveillance via magnetic resonance imaging. This protocol enables the generation and use of a GEM to study lower-grade IDH-mutant gliomas.For complete details on the use and execution of this protocol, please refer to Shi et al. (2022).1

引用

页数：17

共 3 条

[1] D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function
Sasaki, Masato
Knobbe, Christiane B.
Itsumi, Momoe
Elia, Andrew J.
Harris, Isaac S.
Chio, Iok In Christine
Cairns, Rob A.
McCracken, Susan
Wakeham, Andrew
Haight, Jillian
Ten, Annick You
Snow, Bryan
Ueda, Takeshi
Inoue, Satoshi
Yamamoto, Kazuo
Ko, Myunggon
Rao, Anjana
Yen, Katharine E.
Su, Shinsan M.
Mak, Tak Wah
[J]. GENES & DEVELOPMENT, 2012, 26 (18) : 2038 - 2049
[2] IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, Masato
Knobbe, Christiane B.
Munger, Joshua C.
Lind, Evan F.
Brenner, Dirk
Bruestle, Anne
Harris, Isaac S.
Holmes, Roxanne
Wakeham, Andrew
Haight, Jillian
You-Ten, Annick
Li, Wanda Y.
Schalm, Stefanie
Su, Shinsan M.
Virtanen, Carl
Reifenberger, Guido
Ohashi, Pamela S.
Barber, Dwayne L.
Figueroa, Maria E.
Melnick, Ari
Zuniga-Pfluecker, Juan-Carlos
Mak, Tak W.
[J]. NATURE, 2012, 488 (7413) : 656 - +
[3] De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Shi, Diana D.
Savani, Milan R.
Levitt, Michael M.
Wang, Adam C.
Endress, Jennifer E.
Bird, Cylaina E.
Buehler, Joseph
Stopka, Sylwia A.
Regan, Michael S.
Lin, Yu-Fen
Puliyappadamba, Vinesh T.
Gao, Wenhua
Khanal, Januka
Evans, Laura
Lee, Joyce H.
Guo, Lei
Xiao, Yi
Xu, Min
Huang, Bofu
Jennings, Rebecca B.
Bonal, Dennis M.
Martin-Sandoval, Misty S.
Dang, Tammie
Gattie, Lauren C.
Cameron, Amy B.
Lee, Sungwoo
Asara, John M.
Kornblum, Harley I.
Mak, Tak W.
Looper, Ryan E.
Nguyen, Quang-De
Signoretti, Sabina
Gradl, Stefan
Sutter, Andreas
Jeffers, Michael
Janzer, Andreas
Lehrman, Mark A.
Zacharias, Lauren G.
Mathews, Thomas P.
Losman, Julie-Aurore
Richardson, Timothy E.
Cahill, Daniel P.
DeBerardinis, Ralph J.
Ligon, Keith L.
Xu, Lin
Ly, Peter
Agar, Nathalie Y. R.
Abdullah, Kalil G.
Harris, Isaac S.
Kaelin, William G., Jr.
[J]. CANCER CELL, 2022, 40 (09) : 939 - +

← 1 →